|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.12 USD | -1.06% |
|
+5.64% | +24.60% |
| 05-15 | Mizuho Raises Immatics' Price Target to $16 From $14, Keeps Buy Rating | MT |
| 05-14 | Immatics' Q1 Loss Narrows. Revenue Rises | MT |
Immatics Biotechnologies GmbH announced the appointment of Peter Chambr as Chairman of the Board with immediate effect. Peter Chambr has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry. He will replace Thomas Widmann, who has been Chairman of the Company since 2004.
Peter Chambr was CEO of Cambridge Antibody Technology (CAT), from 2002 until its acquisition by AstraZeneca in 2006.
| 1st Jan change | Capi. | |
|---|---|---|
| +24.60% | 1.37B | |
| +16.93% | 124B | |
| +17.01% | 109B | |
| -7.23% | 23.84B | |
| +1.98% | 22.42B | |
| -14.29% | 17.5B | |
| -6.79% | 16.61B | |
| -37.63% | 16.43B | |
| +2.17% | 13.4B | |
| +24.42% | 11.47B |
IMMATICS N.V. 
